Rhinoconjunctivitis Due to Grass Pollen Allergy Clinical Trial
Official title:
A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy in Grass and/or Tree Pollen Allergic Subjects by Intralymphatic Allergen Administration
Allergen specific immunotherapy (SIT) is the only causative treatment of IgE-mediated
allergies. The disadvantages of SIT, however, are the requirement of numerous allergen
administrations over three to five years, and that the treatment itself causes frequent
allergic reactions. We aim at enhancing grass pollen SIT in hay fever patients by injecting
the allergen directly into subcutaneous lymph nodes. In a monocentric randomized trial
safety and efficacy of intralymphatic immunotherapy (ILIT) with 3 low dose grass pollen
extract injections over 2 months are compared to subcutaneous immunotherapy (SCIT) using 54
injections over 3 years.
- Trial with immunodulatory product / biological
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment